Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
British Journal of Cancer (2022 )Cite this article
Cisplatin and gemcitabine (CisGem) are standard chemotherapy for advanced biliary tract cancer (BTC). The MEK inhibitor selumetinib showed synergy with gemcitabine when administered sequentially in BTC. This randomised Phase 2 trial aimed to assess the efficacy of sequential or continuous selumetinib with CisGem.
Patients with advanced BTC received CisGem; arm A included selumetinib every day, arm B: selumetinib, days 1–5, 8–19 each cycle. Arm C received CisGem alone. Selumetinib was dosed at 75 mg BID but amended to 50 mg BID due to toxicity.
In all, 51 participants were evaluable for response. No significant difference was seen in mean change in tumour size at 10 weeks between arms A and C (−7.8% vs −12.8%, P = 0.54) or arms B and C (−15% vs −12.8%, P = 0.78). There was no difference in median progression-free survival (6.0, 7.0, 6.3 months, P > 0.95) or overall survival (11.7, 11.7, 12.8 months, P = 0.70) for arms A, B and C, respectively. More participants experienced grade 3–4 toxicities in selumetinib-containing arms. More participants in arm A required chemotherapy dose reductions (P = 0.01) with lower chemotherapy dose intensity during the first 10 weeks.
Adding sequential or continuous selumetinib to CisGem failed to improve efficacy and increased toxicity in patients with advanced BTC.
This is a preview of subscription content
Get full journal access for 1 year
All prices are NET prices. VAT will be added later in the checkout. Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Supporting data for this study are held by the Drug Development Programme, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353–7. https://doi.org/10.1053/jhep.2001.25087.
CAS Article PubMed Google Scholar
Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pr Res Clin Gastroenterol. 2015;29:221–32. https://doi.org/10.1016/j.bpg.2015.02.003.
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl J Med. 2010;362:1273–81. https://doi.org/10.1056/NEJMoa0908721.
CAS Article PubMed Google Scholar
Wardell CP, Fujita M, Yamada T, Simbolo M, Fassan M, Karlic R, et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol. 2018;68:959–69. https://doi.org/10.1016/j.jhep.2018.01.009.
CAS Article PubMed Google Scholar
Haber PK, Sia D. Translating cancer genomics for precision oncology in biliary tract cancers. Discov Med. 2019;28:255–65.
Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut. 2003;52:706–12. https://doi.org/10.1136/gut.52.5.706.
CAS Article PubMed PubMed Central Google Scholar
Tannapfel A, Benicke M, Katalinic A, Uhlmann D, Köckerling F, Hauss J, et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut. 2000;47:721–7. https://doi.org/10.1136/gut.47.5.721.
CAS Article PubMed PubMed Central Google Scholar
Bridgewater J, Lopes A, Beare S, Duggan M, Lee D, Ricamara M, et al. A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer. 2016;16:153 https://doi.org/10.1186/s12885-016-2174-8.
CAS Article PubMed PubMed Central Google Scholar
Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh J, et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol J Am Soc Clin Oncol. 2011;29:2357–63. https://doi.org/10.1200/JCO.2010.33.9473.
Xu J, Knox JJ, Ibrahimov E, Chen E, Serra S, Tsao M, et al. Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer. Clin Cancer Res. 2013;19:118 LP–127. https://doi.org/10.1158/1078-0432.CCR-12-2557.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026.
CAS Article PubMed Google Scholar
Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of Phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non–small-cell lung cancer. JNCI J Natl Cancer Inst. 2007;99:1455–61. https://doi.org/10.1093/jnci/djm158.
CAS Article PubMed Google Scholar
Lowery MA, Bradley M, Chou JF, Capanu M, Gerst S, Harding JJ, et al. Binimetinib plus gemcitabine and cisplatin phase I/II trial in patients with advanced biliary cancers. Clin Cancer Res. 2019;25:937–45. https://doi.org/10.1158/1078-0432.CCR-18-1927.
CAS Article PubMed Google Scholar
Greystoke A, Steele N, Arkenau H-T, Blackhall F, Haris NM, Lindsay CR, et al. SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. Br J Cancer. 2017;117:938–46. https://doi.org/10.1038/bjc.2017.271.
CAS Article PubMed PubMed Central Google Scholar
Moehler M, Maderer A, Schimanski C, Kanzler S, Denzer U, Kolligs FT, et al. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. Eur J Cancer. 2014;50:3125–35. https://doi.org/10.1016/j.ejca.2014.09.013.
CAS Article PubMed Google Scholar
Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol. 2015;16:967–78. https://doi.org/10.1016/S1470-2045(15)00139-4.
CAS Article PubMed PubMed Central Google Scholar
Demols A, Borbath I, Van den Eynde M, Houbiers G, Peeters M, Marechal R, et al. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial. Ann Oncol. 2020;31:1169–77. https://doi.org/10.1016/j.annonc.2020.05.018.
CAS Article PubMed Google Scholar
Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671–84. https://doi.org/10.1016/S1470-2045(20)30109-1.
CAS Article PubMed PubMed Central Google Scholar
Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796–807. https://doi.org/10.1016/S1470-2045(20)30157-1.
CAS Article PubMed PubMed Central Google Scholar
Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21:1234–43. https://doi.org/10.1016/S1470-2045(20)30321-1.
CAS Article PubMed Google Scholar
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;38:1–10. https://doi.org/10.1200/JCO.19.02105.
Article PubMed PubMed Central Google Scholar
This study was funded as externally sponsored research by AstraZeneca, who provided investigational selumetinib. Additional funding was provided by the Princess Margaret Cancer Foundation.
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
Mark K. Doherty, Raymond Jang, David Hedley, Eric Chen, Neesha Dhani, Hao-Wen Sim, Grainne M. O’Kane & Jennifer J. Knox
Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada
Vincent C. Tam & Patricia Tang
Division of Cancer Sciences, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK
Pharmacy, Princess Margaret Cancer Centre, Toronto, ON, Canada
Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada
Drug Development Program, Princess Margaret Cancer Centre, Toronto, ON, Canada
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
MD—conceptualisation, methodology, investigation and manuscript preparation; VT—investigation, manuscript review; MM—conceptualisation, methodology and manuscript review; RJ—investigation and manuscript review; DH—conceptualisation, investigation and manuscript review; EC—investigation and manuscript review; ND—investigation and manuscript review; PT—investigation and manuscript review; HWS—investigation and manuscript review; GO’K—investigation and manuscript review; SD—resources and investigation; LW—formal analysis; TP—data curation and project administration; JK—conceptualisation, methodology, investigation and manuscript review.
Correspondence to Jennifer J. Knox.
MD received research funding from AstraZeneca and Merck, and speaking honoraria from AstraZeneca, Roche, Merck, Boehringer Ingelheim, Eisai and Takeda. VT received research funding from AstraZeneca, Eisai, Exelixis, Ipsen, Merck, Roche, travel support from Amgen, and speaking honoraria from AstraZeneca, Eisai, Ipsen and Roche. MM received research support from Servier, Ipsen, and NuCana, travel/accommodation support from Bayer and Ipsen, speaker honoraria from Pfizer, Ipsen, NuCana, and Mylan, and consulted for Celgene, Ipsen, Sirtex, Baxalta and Incyte. RJ received research funding from AstraZeneca, Boston Biomedical, Bristol-Myers Squibb, Lilly, Merck and Novartis, and consulted for Ipsen and Novartis. EC received research funding from AstraZeneca, Boston Biomedical, Bristol-Myers Squibb, Merck and Novartis, and speaking honoraria from Bayer, Eisai and Taiho. ND received speaker honoraria from Celgene and Sanofi, and consulted for Celgene and Incyte. PT received travel support from Amgen and consulted for Amgen, AstraZeneca, Celgene, Eisai, Genomic Health International, Merck, Pfizer, Taiho and Teva. HWS received research funding from Abbvie and Bristol-Meiers Squibb. GO’K received speaking honoraria from Eisai and Roche, travel support from AstraZeneca, and consulted for Eisai and Roche. JK received research funding from and consulted for AstraZeneca, Ipsen and Merck, and speaking honoraria from Novartis and Roche. The remaining authors declare no competing interests.
This study was approved by the Research Ethics Boards of the Princess Margaret Cancer Centre and Tom Baker Cancer Centre. All patients provided informed consent and the study was carried out in accordance with the Declaration of Helsinki. The trial was registered with clinicaltrials.gov, ID NCT02151084.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Doherty, M.K., Tam, V.C., McNamara, M.G. et al. Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer. Br J Cancer (2022). https://doi.org/10.1038/s41416-022-01903-6
DOI: https://doi.org/10.1038/s41416-022-01903-6
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
British Journal of Cancer (Br J Cancer) ISSN 1532-1827 (online) ISSN 0007-0920 (print)